Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Masimo Corporation (MASI)

NASDAQ: MASI · Electromedical & Electrotherapeutic Apparatus · Irvine, CA

Our rating: Neutral

First call: Neutral, moderate conviction, at $179.95, moderate conviction, June 10, 2026.

Breaks if: Turn Positive if free cash flow reaches $280M or above on a trailing four-quarter basis within the next 18 months while the GAAP net loss narrows to below $80M, signaling that the non-cash drag is genuinely resolving and growth is beginning to convert to earnings. Turn Cautious if free cash flow falls below $120M on a trailing four-quarter basis at any point in the next 12 months, or if reported revenue growth decelerates to below 5% year-over-year in the next fiscal year disclosed.

Key figures

Market value$9.4B
Revenue, last 12 months$1.6B
Net income, last 12 months$76M
Free cash flow, last 12 months$211M
Price to earnings123.5×
Free cash flow yield2.2%
Dividend yield0.0%
Operating margin19.9%
Return on equity8.8%
Beta to the S&P 5000.97
Volatility, annualized44.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
April 4, 2026$404M8.5%$1.09$41M
January 3, 2026$413M12.0%$1.21$53M
September 27, 2025$372M8.2%$-1.84$51M
June 28, 2025$371M7.9%$0.94$66M
March 29, 2025$372M9.5%$-3.12$29M
December 28, 2024$368M−264.7%$-6.43$44M
September 28, 2024$343M−28.3%$0.18$20M
June 29, 2024$344M−24.5%$0.30$71M

1 ledger entries and 62 corporate events on record. Share price as of June 10, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.